

Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)

September 22, 2018, Houston, Texas

7:00 AM - 3:30 PM

Houston Marriott West Loop By the Galleria 1750 West Loop South, Houston, TX 77027; Phone: (713) 960-0111

Program Director: Eric Jonasch, MD

Jointly provided by



Educational Grants: Ferring Pharmaceuticals Inc; Eisai, Inc

New Date
Sept 22, 2018

Statement of Need/Program Overview

This symposium is intended to improve care of patients with prostate cancer, renal cell carcinoma and urothelial bladder carcinoma by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience

This symposium is directed primarily to hematologists/oncologists, urologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in genitourinary cancers such as prostate cancer, renal cell carcinoma and urothelial bladder carcinoma. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Physicians / Nurses / Pharmacists

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco LLC designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™ for physicians, 5.5 contact hours for nurses and 5.5 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Agenda Topics

- Prostate Cancer Pretest (Case Vignettes - ARS)
- The Current Role of Systemic Therapy in Nonmetastatic Prostate Carcinoma *Eric Jonasch, MD*
- Newly Diagnosed Metastatic Prostate Carcinoma: Has The Paradigm Changed? *Amado Zurita, MD*
- Immunotherapy in Prostate Cancer: Promises and Pitfalls *Sumit Subudhi, MD, PhD*
- Prostate Cancer Posttest (Case Vignettes - ARS)
- Renal Cell Carcinoma Pretest (Case Vignettes - ARS)
- Advances in Multitargeted Kinase Inhibitor in the Treatment of Metastatic Renal Cell Carcinoma (RCC): Lenvatinib *Hans Hammers, MD*
- Update on MET, AXL and VEGF Receptor Inhibitor in the Treatment of Metastatic RCC: Cabozantinib *Eric Jonasch, MD*
- Immunotherapy with Novel PD-1 Checkpoint Inhibitors and Targeted Therapy Combinations in the Treatment of RCC *Nizar M. Tannir, MD*
- Renal Cell Carcinoma Posttest (Case Vignettes - ARS)
- Urothelial Bladder Cancer Pretest (Case Vignettes - ARS)
- Genetic Alterations in the Molecular Subtypes of UBC *Ashish M. Kamat, MD*
- Update on Immunotherapy with PD-1/PD-L1 Antibodies in Patients with UBC *Ashish M. Kamat, MD*
- Urothelial Bladder Cancer Posttest (Case Vignettes - ARS)

For detailed information on faculty, learning objectives and agenda please refer to the www.cancernetus.com

REGISTRATION FORM Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)

First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C NP PhD Pharmacist Industry Nurse Other

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____

E-Mail _____

Specialty _____

Registration Fee (Registration fee includes buffet breakfast, lunch and syllabus book)

	Early Registration Fee - Up to 9/12/18	Discounted Registration Fee - 9/13/18 - 9/15/18	Regular Registration Fee - 9/16/18 - 9/22/18
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

No Refund; Substitution is allowed

Payment may be made: MC Visa Discover Check

Credit Card Number _____ Expiration Date _____

Name and address (as given on the monthly credit card statement) _____

Pharmacist e-profile NABP#: _____ Pharmacist DOB (MMDD): _____

Signature _____

Register online at www.cancernetus.com

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

If you wish to be removed from this fax list, please call 1-866-205-9658 ext. 42870.

Fax registration to:
443-267-0016

Mail registration to:
860 Hebron Pkwy, Suite 1104
Lewisville, TX 75057

Check box to receive information about Live and Webcast programs. You can unsubscribe at any time.